X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs SANOFI INDIA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA SANOFI INDIA GLENMARK PHARMA/
SANOFI INDIA
 
P/E (TTM) x 13.1 34.8 37.7% View Chart
P/BV x 2.4 6.1 38.3% View Chart
Dividend Yield % 0.4 1.4 31.4%  

Financials

 GLENMARK PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
SANOFI INDIA
Dec-18
GLENMARK PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs9306,840 13.6%   
Low Rs5174,630 11.2%   
Sales per share (Unadj.) Rs322.61,203.1 26.8%  
Earnings per share (Unadj.) Rs28.5165.3 17.2%  
Cash flow per share (Unadj.) Rs39.2209.9 18.7%  
Dividends per share (Unadj.) Rs2.0084.00 2.4%  
Dividend yield (eoy) %0.31.5 18.9%  
Book value per share (Unadj.) Rs183.0963.6 19.0%  
Shares outstanding (eoy) m282.1723.03 1,225.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.24.8 47.1%   
Avg P/E ratio x25.434.7 73.2%  
P/CF ratio (eoy) x18.527.3 67.6%  
Price / Book Value ratio x4.06.0 66.4%  
Dividend payout %7.050.8 13.8%   
Avg Mkt Cap Rs m204,206132,078 154.6%   
No. of employees `00013.73.3 415.5%   
Total wages/salary Rs m18,7184,068 460.1%   
Avg. sales/employee Rs Th6,636.88,393.8 79.1%   
Avg. wages/employee Rs Th1,364.71,232.4 110.7%   
Avg. net profit/employee Rs Th586.11,153.0 50.8%   
INCOME DATA
Net Sales Rs m91,03127,708 328.5%  
Other income Rs m914897 101.9%   
Total revenues Rs m91,94528,605 321.4%   
Gross profit Rs m16,1546,235 259.1%  
Depreciation Rs m3,0191,027 293.9%   
Interest Rs m2,8567 40,795.7%   
Profit before tax Rs m11,1936,098 183.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1552,292 137.6%   
Profit after tax Rs m8,0393,806 211.2%  
Gross profit margin %17.722.5 78.9%  
Effective tax rate %28.237.6 75.0%   
Net profit margin %8.813.7 64.3%  
BALANCE SHEET DATA
Current assets Rs m69,88715,922 438.9%   
Current liabilities Rs m32,8796,235 527.3%   
Net working cap to sales %40.735.0 116.3%  
Current ratio x2.12.6 83.2%  
Inventory Days Days8164 127.9%  
Debtors Days Days9321 448.1%  
Net fixed assets Rs m28,8927,539 383.2%   
Share capital Rs m282230 122.7%   
"Free" reserves Rs m51,35321,962 233.8%   
Net worth Rs m51,63522,192 232.7%   
Long term debt Rs m41,4180-   
Total assets Rs m125,95429,839 422.1%  
Interest coverage x4.9872.1 0.6%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.70.9 77.8%   
Return on assets %8.612.8 67.7%  
Return on equity %15.617.2 90.8%  
Return on capital %15.127.5 54.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,3177,587 478.7%   
Fx outflow Rs m9,7207,145 136.0%   
Net fx Rs m26,598442 6,017.5%   
CASH FLOW
From Operations Rs m16,4813,739 440.8%  
From Investments Rs m-10,133-731 1,386.2%  
From Financial Activity Rs m-4,685-1,972 237.6%  
Net Cashflow Rs m1,7701,036 170.8%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 6.9 14.4 47.9%  
FIIs % 34.4 14.6 235.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.5 100.0%  
Shareholders   56,727 15,184 373.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  BIOCON   

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; FMCG and Banking Stocks Gain(12:30 pm)

Stock markets in India are presently trading higher. The BSE Sensex is trading up by 104 points and the NSE Nifty is trading up by 32 points.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 17, 2019 02:35 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS